Trials / Terminated
TerminatedNCT01213823
Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 536 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to estimate the relative risk of severe hepatic injury in hospitalized patients with invasive candidiasis and candidemia who received anidulafungin, compared to patients who received caspofungin and/or micafungin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Does not apply | This is a non-interventional study, therefore the intervention type / name do not apply |
| OTHER | Does not apply | This is a non-interventional study, therefore the intervention type / name do not apply |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2011-05-01
- Completion
- 2011-05-01
- First posted
- 2010-10-04
- Last updated
- 2016-03-30
- Results posted
- 2016-02-04
Source: ClinicalTrials.gov record NCT01213823. Inclusion in this directory is not an endorsement.